Τόμος 20 (2006) – Τεύχος 2 – Άρθρο 52 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 20 (2006) – Issue 2 – Article 52 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Title A preliminary study for the development  of a cyclosporine pharmacokinetic model in renal transplant recipients
Authors Paraskevi F. Katsakiori¹, Dimitrios S. Goumenos², George C. Nikiforidis³ and Christodoulos S. Flordellis¹

1. Department of Pharmacology, School of Medicine, University of Patras

2. Department of Internal Medicine-Nephrology, University Hospital, Patras

3. Department of Medical Physics, School of Medicine, University of Patras, Patra, Greece

Citation Katsakiori, P.F., Goumenos, D.S., Nikiforidis, G.C., Flordellis, Ch.C.: A preliminary study for the development of a cyclosporine pharmacokinetic model in renal transplant recipients, Epitheorese Klin. Farmakol. Farmakokinet. 20(2): 206-207 (2006)
Publication Date Accepted for publication: 19-20 May 2006
Full Text Language English
Order – Buy  Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €) 

pharmakonpress[at]pharmakonpress[.]gr

Keywords Cyclosporine, neoral, population kinetics, pharmacokinetic analysis.
Other Terms review article
Summary Cyclosporine (CsA) is an immunosuppressive agent and its use is impeded by high intra- and inter- individual variability as well as narrow therapeutic index. In order to overcome these problems, therapeutic drug monitoring and dose individualization are necessary. The trial-and-error method, which is used today to estimate the appropriate dosing regimen, is time-consuming and may lead to treatment failure. The aim of our study was to formulate a population pharmacokinetic model for CsA in patients with kidney transplantation. In this direction, we estimated the pharmacokinetic factors that describe its kinetics. For this purpose, fifteen kidney transplant patients were enrolled in the study and analysis of their data was performed with Monte Carlo Markov Chain methodology. Compartmental analysis with one-compartment, first-order absorption model was used throughout the analysis. The values estimated for population kinetic parameters of CsA in renal transplant patients were Clearance/Bioavailability=0.16±0.0012 ml h-1 gr-1, Volume of Distribution/Bioavailability=0.079±0.001 ml gr-1 and (Absorption rate constant- Elimination rate constant)/Bioavailability=3.46±0.13 h-1. These preliminary data shows that the proposed method- ology can lead to more appropriate dosage individualization. The optimization of the model parameters requires more data as well as additional covariates (e.g. hepatic and renal function). Using these additional data, the next step will be the validation of the model in order to estimate its predictability.
References 1. Belitsky P.: Neoral use in the renal transplant recipient. Transplant. Proc. 32 (Suppl 3a): 10S-19S (2000)

2. Keown P.A., D.R.Primmett D.R.: Cyclosporine: The Principal immunosuppresant for renal transplantation. Transplant. Proc. 30: 1712-1715 (1998)

3. Tett S.E., et al.: Population Pharmacokinetics and Pharmacodynamics: An underutilized resource. Drug Information J. 32: 693-710 (1998)

4. Hochhaus G., Derendorf D. (Eds): Handbook of Pharmacokinetic/Pharmacodynamic correlation. Chapt. 4

5. Sheiner L., Wakefield J.: Population modelling in drug development. Statist. Meth. Med. Res. 8: 183-193 (1999)

6. Gilks W.R., Richardson S., Spiiegelhalter D.J. (Eds): Markov Chain Monte Carlo in Practice

7. Markov Chain Monte Carlo (MCMC), Gibbs sampling, Metropolis Algorithms and Simulated Annealing’, 2001 Bioinformatics Course Supplement, SNU Biointelligence Lab (http://bi.snu.ac.krl)

8. Markov Chain Monte Carlo in Practice: A roundtable discussion’, The American Statistician, Vol 52, No 2 (May 1998)

9. Ruggeri A., et al.: A program for the optimization of cyclosporine therapy using population kinetics modeling. Comput. Methods Programs Biomed. 61: 61-69 (2000)

10. Baraldo M., et al.: Pharmacokinetics of two oral cyclosporine A formulations in clinically stable heart-transplant patients. Pharmacol. Res. 43 (No 6), 2001

Relative Papers

Online ISSN 1011-6575

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:

Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor

Τι είναι η Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς – 
What is Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – 
Articles Published in Epitheorese Klinikes Farmakologias 
και Farmakokinetikes-International Edition

Συντακτικη Επιτροπή-Editorial Board

ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 2006 – ANNUAL SUBSCRIPTION 2006
Γλώσσα Πλήρους Κειμένου – Full Text Language Αγγλικά – English
Παραγγελία – Αγορά – Order – Buy Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)

pharmakonpress[at]pharmakonpress[.]gr

Έντυπη Μορφή (70 € + έξοδα αποστολής) – Printed Type (70 € + shipping)

pharmakonpress[at]pharmakonpress[.]gr

 

 

 

 

Bookmark the permalink.

Comments are closed.